Cue Biopharma
Andrey Antov, PhD, MBA has an extensive work experience beginning in 1999 when they were a Thesis Student at the Bulgarian Science Academy's Institute of Ecology. Andrey then went on to become a Research Assistant at the MIT Cancer Center in 2001. In 2003, they became a Graduate Student at Yale University, where they completed their Master's degree in Immunology in 2007. That same year, they were a Summer Intern at McKinsey & Company. In 2004, they were a Summer Intern at Bristol-Myers Squibb, where they worked on establishing a system for a high content screening of potential drugs. In 2009, they were Manager of the Leadership Development Program at Boehringer Ingelheim, where they implemented a new 2,000+ user processing system. From 2011 to 2014, they were Managing Director of the Clinical Sourcing Group at Medpricer, where they were promoted to lead the execution strategy of a new product line. From 2014 to 2016, they were Associated Director and Chief of Staff at The Jackson Laboratory, where they co-developed business plans to reposition the lab as an integrated academic/commercial partner. In 2020, they became Vice President of Enterprise Operations and Portfolio Strategy Leader at Cue Biopharma.
Andrey Antov, PhD, MBA has a comprehensive education history. Andrey obtained their Bachelor degree from Sofia University St. Kliment Ohridski in 1997, majoring in Biology. Andrey then went on to pursue two M.Sc. degrees from the same university, one in Molecular Biology/Biochemistry and the other in Ecology, both of which they completed in 1999. In 2003, they completed an M.Sc./M.Phil. in Biological and Biomedical Sciences/Immunology from Yale University, and in 2009 they completed their PhD in Immunology from the same university. Finally, they obtained an MBA from Yale School of Management in 2009, majoring in Strategy and Marketing. Additionally, they have a certification in PPSA (Proficiency in Photography) from the Photographic Society of America.
This person is not in any offices
Cue Biopharma
1 followers
Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.